JOURNAL OF CLINICAL SURGERY ›› 2025, Vol. 33 ›› Issue (11): 1159-1164.doi: 10.3969/j.issn.1005-6483.20241896

Previous Articles     Next Articles

Analysis of the efficacy of the combined expression of Pokemon,FUNDC1,and p27 in predicting 5-year tumor-free survival after surgery for NSCLC

  

  1. Department of Thoracic Surgery,Affiliated Hospital of Qinghai University,Xining 810000,China
  • Received:2024-11-28 Accepted:2024-11-28 Online:2025-11-20 Published:2025-11-20

Abstract: Objective  To analyze the efficacy of the expression of POK erythroid myeloid carcinogenic factor (Pokemon),mitochondrial autophagy receptor protein FUNDC1,and p27 in predicting the 5-year tumor free survival of non-small cell lung cancer (NSCLC) patients after surgery.Methods A prospective study was conducted on 189 patients with NSCLC who underwent surgical treatment in our hospital from January 2018 to September 2019.According to whether there was tumor free survival after 5 years,patients were divided into tumor-free group and non-tumor-free group.The propensity score matching (PSM) method using the nearest neighbor matching method was applied to reduce selection bias between groups.The general information,surgical specimens Pokemon,FUNDC1,and p27 expression were compared between the two groups before and after PSM.Multivariate Logistic regression analysis was used to analyze the factors associated with 5-year tumor free survival after surgery in NSCLC.The value of the receiver operating characteristic (ROC) curve analysis of the expression of Pokemon,FUNDC1,and p27 in surgical specimens for predicting 5-year tumor free survival in NSCLC patients was investigated.The Kappa value was used to test the consistency between the combined prediction results and the actual clinical results.Results There were significant differences in clinical stage,lymph node metastasis,and vascular tumor thrombus between the first two groups of PSM (P<0.05),while there were no significant differences in age,gender,BMI,family history of cancer,past medical history,tumor diameter,tumor location,and pathological type (P>0.05),there were no significant differences in baseline data between the two groups after PSM (P>0.05),making them comparable.The expression of Pokemon and FUNDC1 in non-tumor group was higher than that in tumor group,while the expression of p27 was lower than that in tumor group (P<0.001).Multivariate Logistic regression analysis showed that after correcting for clinical data such as age and gender,Pokemon and FUNDC1 were still independent risk factors for 5-year tumor free survival after NSCLC surgery,while p27 was an independent protective factor for 5-year tumor free survival after NSCLC surgery (P<0.05).The ROC curve shows that the AUC of Pokemon,FUNDC1,p27,and the combined prediction of 5-year tumor free survival after NSCLC surgery are 0.744,0.783,0.755,and 0.907,respectively (P<0.001).Comparing the AUC of different schemes,the combined AUC is higher than that of Pokemon,FUNDC1,and p27 (Z=3.297,2.673,3.100,P=0.001,0.008,0.002).The external dataset test showed that the consistency between the joint prediction and the actual clinical results was 90.00%,with a Kappa value of 0.769 (P<0.001).Conclusion The expression of Pokemon,FUNDC1,and p27 in surgical specimens is associated with 5year tumor free survival after NSCLC surgery,showing a certain predictive ability.Combined detection can further improve the prognosis after NSCLC resection.

Key words: Pokemon, FUNDC1, p27, combined predictive, non-small cell lung cancer, tumor free survival

[1] . Hot topics and research advances in perioperative immunotherapy for non-small cell lung cancer [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(9): 938-942.
[2] . Opportunities and challenges of neoadjuvant immunotherapy innon-small cell lung cancer [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(9): 943-947.
[3] . Progress in the application of non-intubated video-assisted thoracoscopic surgery for non-small cell lung cancer [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(9): 1003-1006.
[4] QIU Rui,LIU Yang,MA Bo,LYU Zhiping,MA Yunfan. The correlation between ERCC6L expression and clinicopathological characteristics and its prognostic significance in non-small cell lung cancer [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(3): 266-270.
[5] GONG Shunsong,ZHU Yan,DONG Shi,CAI Yixin. Expression of PROM2,RALY and Rab15 in non-small cell lung cancer and their value in predicting the development of bone metastases [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(3): 271-274.
[6] HUANG Rujing, LU Hongling, WU Chao, YANG Hongjuan, YIN Xiaoming, ZHAO Yang, KANG Huawei, TIAN Fei, SUN Yunchuan. Relationship between serum miR-326 and miR-623 expression and clinical pathological characteristics in non-small cell lung cancer patients [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(7): 706-710.
[7] GAO Chao,DAI Xiyong,JIANG Yuhui,LIU Xiaoyu,LI Jing,XIONG Hao. Analysis of the expression levels and clinical diagnostic value of miR-455 and miR-383 in serum of non-small cell lung cancer patients [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(6): 607-610.
[8] WAN Wei,ZHANG Bin,LIU YongZhi,JING Miao,WANG Xiaodong. Efficacy of video-assisted thoracoscopic lobectomy,anatomic segmentectomy and wedge resection in the treatment of non-small cell lung cancer [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(3): 266-270.
[9] SU Zhengjun, HUANG Shanshan, CHEN Wanjin. Diagnostic value of serum ficolin-3 and collagen triple helix repeat containing-1 for non-small cell lung cancer and their relationship with clinicopathological characteristics [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(2): 164-167.
[10] JI Fengjun,LIU Wei,JING Shiyin,WU Bin,YANG Changgang. Analysis of influencing factors and construction of prediction model for cardiac complications in patients with non-small cell lung cancer after endoscopic surgery [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(10): 1040-1043.
[11] YAN Xiaokun, WU Qinghua, CHEN Shaomu, CHENG Zewen. Predictive value of postoperative drainage volume and lung function for pulmonary complications after thoracoscopic lobectomy in patients with non-small cell lung cancer [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(9): 848-851.
[12] Ailijiang· Duolikun, Aizizi· Abulaiti, CHEN Kang. Expression levels and clinical significance of plasma lncRNA ANRIL and miR-191 in patients with non-small cell lung cancer [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(8): 729-732.
[13] LI Dawei, XIA Shihui. Influencing factors of disease-free survival in patients with stage Ⅲ non-small cell lung cancer after neoadjuvant chemotherapy combined with immunotherapy [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(7): 626-629.
[14] ZENG Qiang, ZHANG Yu, CHEN Hui, et al. Leucine-rich-alpha2-glycoprotein 1 regulates proliferation,migration and invasion of non-small cell lung cancer cells through RUNX1/OPN signaling [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(6): 562-567.
[15] JI Shengwei, WANG Ping. Clinical value of microsatellite instability combined with tumor mutation load in evaluating postoperative recurrence and metastasis in NSCLC patients [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(11): 1065-1067.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 729 .
[2] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 732 .
[3] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 735 .
[4] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 747 .
[5] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 753 .
[6] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 760 .
[7] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 766 .
[8] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 777 .
[9] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 780 .
[10] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 783 .